Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30551626 | 1.00 | SNCA (0.34) | SNCAUSP30IRAK4 | |
| SCHEMBL25957470 | 0.91 | SNCA (0.35) | SNCAIRAK4 | |
| SCHEMBL30515101 | 0.87 | SNCA (0.36) | SNCA | |
| SCHEMBL25336632 | 0.87 | SNCA (0.36) | SNCA | |
| SCHEMBL24364822 | 0.86 | SNCA (0.35) | SNCA | |
| SCHEMBL24363858 | 0.84 | NPC1 (0.39) | SNCA | |
| SCHEMBL25923038 | 0.82 | KCNH2 (0.35) | SNCA | |
| SCHEMBL24365160 | 0.82 | SNCA (0.38) | SNCAIRAK4 | |
| SCHEMBL25322736 | 0.81 | SNCA (0.35) | SNCAIRAK4 | |
| SCHEMBL25324181 | 0.81 | SNCA (0.32) | SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | SNCA 1168/4885USP30 2228/4885IRAK4 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.